Oral CT1812 therapy is used to treat geographic atrophy secondary to dry age-related macular degeneration. Credit: Image Point Fr/Shutterstock.com.

Cognition Therapeutics has dosed the first participant in its Phase II MAGNIFY study of oral CT1812 therapy to treat geographic atrophy (GA) secondary to dry age-related macular degeneration (dry AMD).

Dr David Almeida, who is currently working as a vitreoretinal surgeon and is the president, CEO, and director of clinical research at Erie Retinal Surgery in Pennsylvania, enrolled the first participant in the trial.

Go deeper with GlobalData

Data Insights

The gold standard of business intelligence.

Find out more

Related Company Profiles

View all

Cognition Therapeutics president and CEO Lisa Ricciardi said: “As Dr Almeida mentioned, dry AMD is complex, with many underlying disease drivers.

“Our research suggests that a sigma-2 (σ-2) modulator, such as CT1812, has the potential to protect RPE cells from several of these key drivers, which may allow patients to retain their visual acuity for longer.

“We look forward to working with Dr Almeida and our other investigators to explore this possibility in the MAGNIFY study.”

See Also:

The placebo-controlled, randomised MAGNIFY study intends to enrol approximately 246 adults diagnosed with dry AMD with measurable GA.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

Patients will receive a once-daily oral dose of CT1812 for 24 months to determine if it can slow the progress of the disease as measured by GA lesion size changes.

An estimated five million people globally and one million in the US are suffering from dry AMD.

Dr Almeida added: “Until recently, there were no FDA-approved medications for our patients with dry AMD.

“I am in sincere gratitude to our patients who support our search for novel therapeutics and I’m thankful for the dedication and skill I see working with our Cognition Therapeutics partners to explore the potential of CT1812 in our patients.”

In addition to dry AMD, Cognition is also investigating CT1812 in its clinical programmes for treating Alzheimer’s disease and dementia with Lewy bodies.